ClinicalTrials.gg
CompletedNCT05187533Updated Nov 1, 2024

Sphenopalatine Ganglion Stimulation for Ocular and Oral Dryness

An interventional study of Osteopathic protocol of Sphenopalatine Ganglion Stimulation in Dry Eye Disease and Xerostomia, sponsored by Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA. Completed at 1 site in Spain. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-11-01.

Sponsored by Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Dry Eye Syndromes with a site in Spain — 3 open to participants now, 4 under way, none of them phase 3. Dry Eye Syndromes · Spain.

Enrollment
30th of 41
30 · median 60
Started
2022
with 4 others
No phase
21 of 44
1 open now
Registered
25th of 44
by date
Lead sponsor
5 of 44
Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA

Among the 44 studies in Dry Eye Syndromes with a site in Spain, this one is the 30th largest by enrollment of the 41 interventional ones that give a count, is one of 5 that started in 2022, is one of 21 with no phase, and was the 25th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

3 of the 44 studies in Dry Eye Syndromes with a site in Spain are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Dry Eye Syndromes with a site in Spain, or all of them as a file.
02

Study summary

Dry Eye Disease (DED) is a multifactorial pathology characterized by inflammation of the lacrimal functional unit that develops in ocular surface pathology, severely affecting patients quality of life. The core of the treatment relies at present in antinflammatory topical therapies, which are still scarce.

The investigators hypothesize that osteopathy-based techniques may help these patients by influencing the central involvement regarding parasympathetic innervation of tear and saliva-secreting glands.

The aim of this osteopathic treatment protocol is to release the involved structures in the tear-secreting system innervation, such as the sphenopalatine ganglion. In addition, this ganglion innervates the minor salivary glands, therefore it is intended to help patients suffering from xerostomia.

The hypothesis then is that a systemic protocol treatment can help balance both parts of the vegetative nervous system (sympathetic and parasympathetic) with the objective of increasing the secretion of tear and saliva in patients with ocular and oral dryness (DED and xerostomia, respectively), thus improving their clinical situation.

This osteopathic protocol does not have the potential to cause adverse effects. The main objective is to analyze the efficacy of this protocol application in terms of improving symptoms and signs of ocular and oral dryness, tear film quality and inflammation molecule levels in tears and saliva.

Read the detailed description

This clinical study intended to offer an alternative therapeutic tool for a disease, dry eye, that is highly prevalent, causes a decreased in the quality of life and work productivity, and whose pharmacologic treatment is very limited.

The osteopathy protocol consists of an initial assessment of the cranial vault and 7 techniques through which the different structures involved are treated and are as follows: 1) balance of the cranio-sacral system; 2) reharmonization of sphenobasilar synchondrosis; 3) and 4) release of the bony components in the pterygo-palatine fossa (maxillas and sphenoid); 5) and 6) release of the bony components in relation with the main lacrimal gland (frontal and front-malar suture); and 7) sphenopalatine ganglion stimulation. The patient is always in supine position and the investigator is standing on the side.

The proposed osteopathy protocol is innocuous, with no possible adverse effects. The main objective is to analyze the efficacy of this protocol application in terms of improving symptoms and signs of ocular and oral dryness, tear film quality and inflammation molecule levels in tears and saliva.

Recruited patients will have dry eye disease (and subsequently ocular dryness) and oral dryness (xerostomia). Inclusion/exclusion criteria are detailed in the corresponding section below, as well as all outcome measures.

All COVID19-related sanitary regulations will be strictly followed.

03

Conditions studied

  • Dry Eye Disease
  • Xerostomia

Keywords

  • dry eye disease
  • dryness
  • osteopathy
  • Keratoconjunctivitis sicca
  • Saliva cytokines
  • Saliva-producing glands
  • Sjögren´s syndrome
  • Sphenopalatine ganglion
  • Tear-producing glands
  • Tear cytokines
  • Tear film
  • Xerostomia
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • > 18 years old.
  • Patients diagnosed with Dry eye disease (DED) and suffering symptoms of ocular and oral dryness for at least 6 months.
  • "Dry eye" symptoms must have a score of > 2 (0-4 range) in mSIDEQ questionnaire.
  • Ocularly symptomatic patients (OSDI > 12) despite the medication, medical devices and/or therapeutic measures carried out until the inclusion.
  • Symptomatic patients in terms of oral dryness (XI-Sp > 11) despite the medication, medical devices and/or therapeutic measures carried out until the inclusion.
  • Schirmer I test, without topical anesthesia, must have an initial value of ≥ 1 mm and \<10 mm.
  • Not included in any other clinical pharmacological trial or study (medical devices are excluded) in the last 3 months.
  • Signed and ability to complete all study visits.

Exclusion criteria

Exclusion Criteria:

  • Irreversible anatomical alteration of the lacrimal glands (watery, sebaceous or mucinic) or salivary, surgeries or by healing processes that affect eyelids and/or conjunctiva.
  • Alteration in the autonomic nervous system.
  • Another active ocular surface disease different from that caused by DED.
  • Oral diseases, inflammations or acute injuries in the mouth (trauma, surgical intervention, etc.) in the last month or healing processes of the oral mucosa.
  • Use of cyclosporine or topical tacrolimus started within \< 3 months and/or or blood derivatives started within \< 1 month and that will not be maintained during the study.
  • Use of orally drugs with exocrine hyposecretory side effects or that may affect the parasympathetic nervous system, unless the dose is stable during the previous month to inclusion and whose dose is not expected to vary throughout this study.
  • Patients may be using any other medication, topical or systemic, unless the dose are the same for the duration of the study.
  • Patients may be using artificial tears, moisturizers in general or blood derivatives, unless the dose was the same in the last month and has to be maintained at the same dose for the duration of the study.
  • To have had any "in-office" method to manage DED or Meibomian gland dysfunction (pulsed light, thermal massages, etc.) in the last 6 months.
  • Occlusion of the lacrimal puncta in the last month.
  • Local (in cranial sphere) or general anesthesia in the last 3 months.
  • Use of contact lenses, unless they stop using them for at least one week before inclusion and one week before each visit
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Other
    Mild dry eye disease

    Osteopathic protocol of sphenopalatine ganglion stimulation

    Other: Osteopathic protocol of Sphenopalatine Ganglion Stimulation

  • Other
    Moderate dry eye disease

    Osteopathic protocol of sphenopalatine ganglion stimulation

    Other: Osteopathic protocol of Sphenopalatine Ganglion Stimulation

  • Other
    Severe dry eye disease

    Osteopathic protocol of sphenopalatine ganglion stimulation

    Other: Osteopathic protocol of Sphenopalatine Ganglion Stimulation

Interventions

  • OtherOsteopathic protocol of Sphenopalatine Ganglion Stimulation

    Sphenopalatine Ganglion Stimulation to improve lacrimal and salivary gland secretion to improve ocular and oral dryness

06

What researchers measure

Primary outcomes

  1. Ocular Surface Disease Index (OSDI)

    Score value 0-48, where higher score means a worse outcome.

    Time frame: 6 Weeks

  2. Ocular Surface Disease Index (OSDI)

    Score value 0-48, where higher score means a worse outcome.

    Time frame: 18 Weeks

  3. Modified Single-Item Score Dry Eye-Questionnaire (mSIDEQ)

    Score value 0-28, where higher score means a worse outcome

    Time frame: 6 Weeks

  4. Modified Single-Item Score Dry Eye-Questionnaire (mSIDEQ)

    Score value 0-28, where higher score means a worse outcome

    Time frame: 18 Weeks

  5. Visual analogue Scale (VAS)

    Unique measurements 0-10, where higher score means a worse outcome

    Time frame: 6 Weeks

  6. Visual analogue Scale (VAS)

    Unique measurements 0-10, where higher score means a worse outcome

    Time frame: 18 Weeks

  7. Change in Dry Eye Symptoms Questionnaire (CDES-Q)

    First question compares how the patient is at the moment compared with last session in terms of "Equal", "Better" or "Worse". If better or worse is chose, two more questions measure how much improvement or worsening from a 0-10 scale, where higher score means a worse outcome.

    Time frame: 6 Weeks

  8. Change in Dry Eye Symptoms Questionnaire (CDES-Q)

    First question compares how the patient is at the moment compared with last session in terms of "Equal", "Better" or "Worse". If better or worse is chose, two more questions measure how much improvement or worsening from a 0-10 scale, where higher score means a worse outcome.

    Time frame: 18 Weeks

  9. Statistically significant amelioration in oral symptoms

    Enhancement in Xerostomia Inventory Spanish version (XI-Sp) test score 0-11, where higher score means a worse outcome.

    Time frame: 6 Weeks

  10. Statistically significant amelioration in oral symptoms

    Enhancement in Xerostomia Inventory Spanish version (XI-Sp) test score 0-11, where higher score means a worse outcome.

    Time frame: 18 Weeks

  11. Statistically significant improvement in tear secretion

    Schirmer I test, which test score is 0-35 mm, where lower score means a worse outcome.

    Time frame: 6 Weeks

  12. Statistically significant improvement in tear secretion

    Schirmer I test, which test score is 0-35 mm, where lower score means a worse outcome.

    Time frame: 18 Weeks

  13. Statistically significant improvement in salivary discharge

    Salivary flow rate, where flow rate below 0,1ml flow is considered hyposalivation.

    Time frame: 6 Weeks

  14. Statistically significant improvement in salivary discharge

    Salivary flow rate, where flow rate below 0,1ml flow is considered hyposalivation.

    Time frame: 18 Weeks

Secondary outcomes

  1. Decrease in tear collection time

    Statistically significant improvement in tear collection time, using a microcapillar of 1μl.

    Time frame: 18 Weeks

  2. Increased salivary flow rate

    Statistically significant increased salivary flow rate, using Modified Fox Sreebny Technique.

    Time frame: 18 Weeks

  3. Lipiflow interferometry - lipid layer thickness

    Statistically significant improvement in lipid layer thickness using Interferometry with Lipiview.

    Time frame: 18 Weeks

  4. Lipiflow interferometry - incomplete blink rate

    Statistically significant improvement in incomplete blink rate using Interferometry with Lipiview.

    Time frame: 18 Weeks

  5. Lipiflow interferometry - c-factor

    Statistically significant improvement in c-factor, using Interferometry with Lipiview.

    Time frame: 18 Weeks

  6. Enhancement in Break-Up Time Test

    Statistically significant enhancement in Break-Up Time Test (normal \>7 seconds) where lower score means a worse outcome.

    Time frame: 18 Weeks

  7. Corneal Staining

    Statistically significant enhancement in Corneal Staining, using Oxford Scale and Cornea and Contact Lens Research Unit (CCLRU) Scale, score 0-5 where higher scores means worse outcome.

    Time frame: 18 Weeks

  8. Significant beneficial change in molecules evaluated in tear or saliva

    The following putative salivary indicators of pain are assayed by enzyme-linked immunosorbent assay (ELISA): Cortisol (DRG Salivary Cortisol ELISA (DRG Instruments GmbH, Marburg, Germany), testosterone (DRG Instruments GmbH), sTNFαRII (Quantikine, Human sTNF RII/TNFRSF1B Immunoassay, R\&D Systems, Minneapolis, MN, USA). sAA is

    Time frame: 18 Weeks

07

Study locations

1 site
  • IOBA
    Valladolid, 47011, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Oct 2024, 33 months.

Of 200 non-industry interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 25. This study's 33 months is above that.

Counting every sponsor, half of 315 studies reached it within 10 months; a quarter within 4 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2021
First posted
Jan 12, 2022
StartActual
Jan 15, 2022
Primary completionActual
Oct 30, 2024
CompletionActual
Oct 30, 2024
Last update
Nov 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05187533
Lead sponsor
Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
Responsible party
Sponsor
First posted
Jan 12, 2022
Start date
Jan 15, 2022
Primary completion
Oct 30, 2024
Completion
Oct 30, 2024
Last update
Nov 1, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion